Low Rate of Clinically Evident Extravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with a Complement C5 Inhibitor: Results from a Large, Multicenter, US Real-World Study

PURPOSE: Most patients with paroxysmal nocturnal hemoglobinuria (PNH) treated with a complement protein 5 (C5) inhibitor achieve full control of terminal complement activity and intravascular hemolysis. The minority remains anemic and transfusion dependent despite this control. Etiology for ongoing...

Descripción completa

Detalles Bibliográficos
Autores principales: Shammo, Jamile, Gajra, Ajeet, Patel, Yogesh, Tomazos, Ioannis, Kish, Jonathan, Hill, Anita, Sierra, J Rafael, Araten, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9380823/
https://www.ncbi.nlm.nih.gov/pubmed/35983240
http://dx.doi.org/10.2147/JBM.S361863

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9380823/
https://www.ncbi.nlm.nih.gov/pubmed/35983240
http://dx.doi.org/10.2147/JBM.S361863

Ejemplares similares